2021 looks set to be a big year for cannabis reform in the US now that the new White House administration has signalled that cannabis reform is one of its top priorities, and the US public supports cannabis reform in unprecedented numbers.
Keep up to date with the latest changes in federal regulation impacting the US market for CBD market with news, data and research at the CBD-Intel hub.
Tim Phillips, CBD-Intel’s managing director, recently presented at CBD Live during VOXPO – Virtual Online Vape & CBD Expo on 28th April 2021. In addition to an overview of the impact of Covid-19 on the retail environment, he provided a comparative analysis of the current Novel Food legislation in the UK and the US, as […]
Significant cannabis reform is inevitably coming to congress, no matter whether the Biden administration considers it a priority, and giants in experienced lobbying industries are preparing their agents
Access to banking services has been a problem for the legal cannabis sector in the US from the beginning – and the experience of one cooperative in Michigan shows that the relationship can be problematic for financial institutions too
The US Customs and Border Protection (CBP) agency is wrongly seizing legal hemp and hemp-related shipments – such as farm equipment that it claims constitutes drug paraphernalia – according to two recently-filed lawsuits
The US Food and Drug Administration (FDA) has assessed a combined health claim for the first time and denounced the practice of promoting CBD on a product making qualified health claims based on other ingredients
The US Food and Drug Administration (FDA) has told two CBD companies they fell short of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and ordered them to undertake proper testing
Podcasts editor Jon Bruford is joined by Anthony Traurig, CBD-Intel legal analyst and US specialist, to discuss the legal and regulatory concerns that hang over cannabis in the US and Canada and the economic impact of Covid-19
The heir to the Wrigley’s chewing gum fortune, Beau Wrigley, has entered into a deal he claims will accelerate the growth of his multi-state cannabis company, Parallel, and change the landscape of the US cannabis market
Marlboro cigarette manufacturer Altria has stated its support for the federal legalisation of cannabis – with a view to Cronos, the Canadian cannabis company in which it has a major stake, thriving in a legal US market
The Democratic Party, which now controls Congress and the presidency, has signalled for some time that cannabis reform is one of its top priorities, and the US public supports that reform in unprecedented numbers
President elect Joe Biden still looks to be somewhat reluctant to too closely embrace cannabis reform as an issue. But effective control of the senate through victories by Raphael Warnock and Jon Ossoff in special run-off elections in the state of Georgia give Democrats 48 seats with two independents that generally vote democratic (and would […]
Multiple jurisdictions are planning significant legislation on both CBD and hemp-related matters, but it seems regulation in 2021 could be defined as much by what doesn’t happen as by the progress made
The US Food and Drug Administration (FDA) is still working on a plan to standardise a baseline level of regulation for CBD in dietary supplements, food and drinks – but many in the industry and at state level are weary of waiting
Berta Camps Bisbal, CBD-Intel’s senior legal analyst, presented a comparative analysis of state laws in the US at CBD Live during VOXPO – Virtual Online Vape & CBD Expo on 18th November. She presented an overview of the federal farm bill as well as CBD at the federal level versus state level. You can now […]
Well reported studies of labelling issues give unfair bad press to CBD – but it is an issue the industry urgently needs to address, according to speakers at the Food and Drug Law Institute’s annual conference
The US House of Representatives is expected to hold a historic vote this month on a comprehensive cannabis reform bill that supporters embrace for not only decriminalising marijuana but correcting injustices
First it’s important to note that the DEA proposals are only in a draft form and are open to comment until 20th October. They have already received a large number of comments, the majority of which appear to be criticising aspects of the proposed regulatory regime that have raised hackles among the industry.
Current indications are that the EC is leaning heavily towards the idea that CBD does indeed count as a narcotic under the 1961 Un Convention.
In December 2018 the Farm Bill removed hemp – defined as cannabis – and its derivatives, from the definition of marijuana in the Controlled Substances Act.
This paved the way for the legal cultivation, sale and distribution of the hemp plant but also led to led to the misperception that all products made from or containing hemp, including those made with CBD, were now legal to sell in interstate commerce.
Two years on, there is still a lack of clarity around what is and isn’t legal and the CBD industry is held back by lack of federal regulation and a patchwork of consumer and products safety standards and guidance.
Industry stakeholders have called for more joined up regulation, including increased protection of state legalisation frameworks, access to banking for cannabis firms, harmonised standards for consumer and product safety and lab testing, and relaxation of federal constraints on research.
With frustrations mounting over the Food and Drug Administration’s (FDA’s) slow pace, Congress could take matters into its own hands by passing legislation to move the industry forward.
Though Biden himself seemingly remains sceptical about recreational cannabis – having previously stated it should be placed in Schedule II under the Controlled Substances Act category – many of his major appointments appear to be solid supporters of hemp and cannabis, which gives the industry reason for optimism.
Stay on top of the ever-changing regulatory landscape with our CBD-Intel hub, which provides access to our news briefings, data and reports on developments related to US federal regulation.
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
Medical and recreational cannabis – a global overview
Check out our new regulatory data on medical and recreational cannabis in 54 jurisdictions around the world
The report, accompanied by a more detailed database, provides an overview of the regulatory situation in the selected countries, using maps, and assesses the likelihood that the status quo may change in the future.